📊 XBIT Key Takeaways
Is XBiotech Inc. (XBIT) a Good Investment?
XBiotech is a pre-revenue pharmaceutical company with zero sales and persistent operating losses of $6.3M annually, indicating a failed commercialization strategy or indefinite development stage. While the $115.5M cash position provides 12+ years of runway, the complete absence of revenue generation with no clear path to profitability represents fundamental business model failure for a public company.
Why Buy XBiotech Inc. Stock? XBIT Key Strengths
- Exceptional liquidity with $115.5M cash and 39x current ratio
- Minimal debt burden (0.00x debt-to-equity) with only $4.8M liabilities
- Strong balance sheet provides extended runway for business transition
XBIT Stock Risks: XBiotech Inc. Investment Risks
- Zero revenue generation indicates complete commercialization failure
- Persistent operating losses of $6.3M annually with negative cash flow
- No insider purchases in 90 days signals management lack of confidence
- Pre-revenue biotech with undefined path to profitability or product approval
- Negative ROE (-4.1%) and ROA (-3.9%) demonstrate ongoing shareholder value destruction
Key Metrics to Watch
- Revenue generation and product commercialization milestones
- Operating cash flow trend and burn rate acceleration/deceleration
- Cash depletion rate relative to remaining runway
- Clinical trial progress and regulatory approval timeline
XBiotech Inc. (XBIT) Financial Metrics & Key Ratios
💡 AI Analyst Insight
Strong liquidity with a 39.03x current ratio provides a solid financial cushion.
XBIT Profit Margin, ROE & Profitability Analysis
XBIT vs Healthcare Sector: How XBiotech Inc. Compares
How XBiotech Inc. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is XBiotech Inc. Stock Overvalued? XBIT Valuation Analysis 2026
Based on fundamental analysis, XBiotech Inc. has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
XBiotech Inc. Balance Sheet: XBIT Debt, Cash & Liquidity
XBIT Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: XBiotech Inc.'s revenue has declined by 91% over the 5-year period, indicating business contraction. The most recent EPS of $-1.26 indicates the company is currently unprofitable.
XBIT Revenue Growth, EPS Growth & YoY Performance
XBIT Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2023 | N/A | -$7.4M | $-0.24 |
| Q2 2023 | N/A | -$8.7M | $-0.29 |
| Q1 2023 | N/A | -$3.8M | $-0.13 |
| Q3 2022 | $1.7M | -$3.3M | $-0.11 |
| Q2 2022 | $1.5M | -$4.8M | $-0.17 |
| Q1 2022 | $500.0K | -$2.2M | $-0.09 |
| Q3 2021 | $4.5M | -$2.5M | N/A |
| Q2 2021 | $4.5M | -$4.8M | N/A |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
XBiotech Inc. Dividends, Buybacks & Capital Allocation
XBIT SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for XBiotech Inc. (CIK: 0001626878)
📋 Recent SEC Filings
❓ Frequently Asked Questions about XBIT
What is the AI rating for XBIT?
XBiotech Inc. (XBIT) has an AI rating of STRONG SELL with 75% confidence, based on fundamental analysis of SEC EDGAR filings.
What are XBIT's key strengths?
Claude: Exceptional liquidity with $115.5M cash and 39x current ratio. Minimal debt burden (0.00x debt-to-equity) with only $4.8M liabilities.
What are the risks of investing in XBIT?
Claude: Zero revenue generation indicates complete commercialization failure. Persistent operating losses of $6.3M annually with negative cash flow.
What is XBIT's revenue and growth?
XBiotech Inc. reported revenue of $0.0.
Does XBIT pay dividends?
XBiotech Inc. does not currently pay dividends.
Where can I find XBIT SEC filings?
Official SEC filings for XBiotech Inc. (CIK: 0001626878) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is XBIT's EPS?
XBiotech Inc. has a diluted EPS of $-1.49.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is XBIT a good stock to buy right now?
Based on our AI fundamental analysis in May 2026, XBiotech Inc. has a STRONG SELL rating with 75% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.
Is XBIT stock overvalued or undervalued?
Valuation metrics for XBIT: ROE of -4.1% (sector avg: 15%), net margin of N/A (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
Should I buy XBIT stock in 2026?
Our dual AI analysis gives XBiotech Inc. a combined STRONG SELL rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is XBIT's free cash flow?
XBiotech Inc.'s operating cash flow is $-9.0M, with capital expenditures of $0.0.
How does XBIT compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin N/A (avg: 12%), ROE -4.1% (avg: 15%), current ratio 39.03 (avg: 2).